Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Investor Presentation
Intimation regarding Corporate Presentation for Q1 FY2408-08-2023
08-08-2023
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meetings.03-08-2023
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation regarding Schedule of Investor/ Analyst Meetings02-08-2023
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of conference call on Financial Results for Q1 FY2402-08-2023
Moneycontrol Pro Panorama | Even in a weakened state, China's overhang over metals to continue
In today's edition of Moneycontrol Pro Panorama: India's drug regulation process needs overhaul, price hikes effect Dr Lal PathLabs' performance, no push to the climate agenda at G20 summit, and more31-07-2023
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Announcement regarding Allotment of ESOP28-07-2023
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of Newspaper Advertisement of Financial Results for Quarter ended June 30,2023.28-07-2023
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 and 46(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that the audio recording of the Company's Conference Call dated July 27, 2023 with Investors/ Analysts for Q1 FY24 is available on the Company's website at https://www.lalpathlabs.com/investors/investors-inside/quarterly-result27-07-2023
Dr. Lal Pathlabs Results Earnings Call for Q1FY24
Conference Call with Dr. Lal Pathlabs Management and Analysts on Q1FY24 Performance and Outlook. Listen to the full earnings transcript.27-07-2023
Q1FY24 Quarterly Result Announced for Dr. Lal Pathlabs Ltd.
Healthcare Services company Dr. Lal Pathlabs announced Q1FY24 results: Revenue of Rs 541 crore in Q1FY24 compared to Rs 503 crore in Q1FY23, up 7.6% YoY Non-Covid Revenue increased by 9.7% to Rs 528 crore in Q1FY24 Normalised EBITDA margin (after adjustment for stock-based compensation & CSR) for Q1FY24 is 28.4% PAT margin for Q1FY24 is 15.4% Result PDF27-07-2023